IDEXX Laboratories Stock Surges 6.6% in Premarket Trading

IDEXX Laboratories, Inc. (IDXX) has seen a significant uptick in its stock price in premarket trading, rising by 27.94 points or 6.6%. The current premarket price stands at $449.993.

This impressive movement can be attributed to the recent announcement of the company's fourth quarter and full year 2024 results, which showcased solid revenue growth and earnings performance. The company reported a 6% increase in revenue for the fourth quarter, reaching $954 million, driven primarily by the Companion Animal Group (CAG) Diagnostics, which also saw a 6% growth.

Furthermore, IDEXX delivered a fourth-quarter earnings per share (EPS) of $2.62, representing a 13% increase from the prior year. These results underscore the company’s effective execution strategies and expansion of its global premium instrument installed base.

Looking forward, IDEXX has set an optimistic outlook for 2025, anticipating revenue growth between $4,055 million and $4,170 million and projecting an EPS range of $11.74 to $12.24. This guidance reflects expected continued growth in recurring revenue from the CAG Diagnostics segment and ongoing share repurchase initiatives.

Overall, the combination of strong quarterly results and a positive forecast for the upcoming year has contributed to the robust performance of IDXX in premarket trading.